NeuroDerm is developing ND0612 for the treatment of moderate to severe stage Parkinson’s disease patients for whom oral drugs are no longer effective enough. ND0612 has been designed to be a safer, more effective and convenient alternative to current treatment modalities that involve surgery, such as deep brain stimulation (DBS) and levodopa/carbidopa intestinal gel (LCIG, Duodopa in Europe and Duopa in the United States).
ND0612 belt pump
A simple, daily, convenient drug pump that delivers LD/CD to treat severe Parkinson’s disease patients.
ND0612 has been designed to provide continuous subcutaneous delivery of an adjustable, LD/CD formulation to significantly improve motor and non-motor complications in patients treated with oral LD/CD.
ND0612 subcutaneous administration – utilizing a convenient belt-pump (resembling the administration of insulin to diabetic patients) – allows patients to receive continuous LD/CD therapy on a 24 hour basis, thus improving morning “off” time and ensuring a good night’s sleep.
NeuroDerm believes that ND0612 will be a first-line treatment alternative for Parkinson’s patients experiencing motor fluctuations, preceding and replacing the surgical treatment alternatives currently offered to severe stage patients.
NeuroDerm completed a Phase II program with ND0612. In these studies, plasma levodopa concentrations achieved in Parkinson’s disease patients, as well as efficacy measurements demonstrated with ND0612 indicate that ND0612 may offer a viable alternative to more invasive surgical procedures for advanced Parkinson’s Disease.